Penny stock player Adamis gets another CRL for high-dose naloxone as shares crater

The FDA has once again shut the door on micro cap biotech Adamis Pharmaceuticals’ high dose naloxone injection.

Regulators handed down the program’s second CRL in nearly 12 months, Adamis announced Monday, sending the penny stock spiraling.